Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 2/20 | 0.62 |
| ▸ | JAK3 | P52333 | 7/20 | 0.52 |
| ▸ | JAK2 | O60674 | 6/20 | 0.52 |
| ▸ | JAK1 | P23458 | 2/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.49 |
| ▸ | SRC | P12931 | 3/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30405231 | 1.00 | TGFBR1 (0.62) | TGFBR1JAK3JAK2JAK1FGFR1 | |
| SCHEMBL17267691 | 0.94 | TGFBR1 (0.64) | TGFBR1JAK3JAK2JAK1FGFR1 | |
| SCHEMBL31046956 | 0.94 | TGFBR1 (0.64) | TGFBR1JAK3JAK2JAK1FGFR1 | |
| SCHEMBL17267609 | 0.90 | TGFBR1 (0.54) | TGFBR1JAK3JAK2JAK1FGFR1 | |
| SCHEMBL31046965 | 0.90 | TGFBR1 (0.54) | TGFBR1JAK3JAK2JAK1FGFR1 | |
| SCHEMBL17267741 | 0.89 | TGFBR1 (0.58) | TGFBR1JAK3JAK2JAK1FGFR1 | |
| SCHEMBL2965560 | 0.85 | SRC (0.58) | TGFBR1JAK3JAK2JAK1FGFR1 | |
| SCHEMBL29503478 | 0.85 | SRC (0.58) | TGFBR1JAK3JAK2JAK1FGFR1 | |
| SCHEMBL23150464 | 0.84 | JAK3 (0.59) | TGFBR1JAK3JAK2JAK1FGFR1 | |
| SCHEMBL31071097 | 0.84 | TGFBR1 (0.46) | TGFBR1JAK3JAK2SRCEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12544448-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250108117-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-04-03 | — | — | US | disclosed |
| US-12187746-B2 | C26-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2025-01-07 | — | — | US | disclosed |
| CN-118978535-A | C40-, C28-and C32-linked rapamycin analogues as mTOR inhibitors | 锐新医药公司 | 2024-11-19 | — | — | CN | disclosed |
| CN-118894869-A | C40-, C28-and C32-linked rapamycin analogues as mTOR inhibitors | 锐新医药公司 | 2024-11-05 | — | — | CN | disclosed |
| EP-3788050-B1 | C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | REVOLUTION MEDICINES INC (US) | 2024-08-28 | — | — | EP | disclosed |
| CN-112771054-B | C40-, C28-and C32-linked rapamycin analogues as mTOR inhibitors | 锐新医药公司 | 2024-08-16 | — | — | CN | disclosed |
| US-12048749-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20240166667-A1 | C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-05-23 | — | — | US | disclosed |
| EP-4234031-A2 | C40-, C28-, AND C-32-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-9765037-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2017-09-19 | — | — | US | disclosed |
| US-9580432-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-02-28 | — | — | US | disclosed |
| WO-2016123151-A1 | BUMPED KINASE INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | UNIVERSITY OF WASHINGTON (US) | 2016-08-04 | — | — | WO | disclosed |
| WO-2016123151-A1 | BUMPED KINASE INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | UNIVERSITY OF WASHINGTON (US) | 2016-08-04 | — | — | WO | disclosed |
| WO-2016123152-A1 | COMPOSITIONS AND METHODS FOR TREATING TOXOPLASMOSIS, CRYPTOSPORIDIOSIS AND OTHER APICOMPLEXAN PROTOZOAN RELATED DISEASES | UNIVERSITY OF WASHINGTON (US) | 2016-08-04 | — | — | WO | disclosed |
| WO-2016123152-A1 | COMPOSITIONS AND METHODS FOR TREATING TOXOPLASMOSIS, CRYPTOSPORIDIOSIS AND OTHER APICOMPLEXAN PROTOZOAN RELATED DISEASES | UNIVERSITY OF WASHINGTON (US) | 2016-08-04 | — | — | WO | disclosed |
| US-20160115168-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-04-28 | — | — | US | disclosed |
| EP-2947086-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2015-11-25 | — | — | EP | disclosed |
| US-20130018040-A1 | Compositions And Methods For Treating Toxoplasmosis, Cryptosporidiosis, And Other Apicomplexan Protozoan Related Diseases | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130018040-A1 | Compositions And Methods For Treating Toxoplasmosis, Cryptosporidiosis, And Other Apicomplexan Protozoan Related Diseases | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018040-A1 | Compositions And Methods For Treating Toxoplasmosis, Cryptosporidiosis, And Other Apicomplexan Protozoan Related Diseases | PNCK, TXK, CILK1 | TGFBR1 3071/4885JAK3 412/4885JAK2 381/4885 |
| US-20250108117-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | MTOR, RICTOR, RPTOR | TGFBR1 3567/4885JAK3 2887/4885JAK2 803/4885 |
| US-12048749-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | TGFBR1 3567/4885JAK3 2887/4885JAK2 803/4885 |
| US-12187746-B2 | C26-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | TGFBR1 3678/4885JAK3 2746/4885JAK2 642/4885 |
| US-20240166667-A1 | C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | MTOR, RICTOR, RPTOR | TGFBR1 3678/4885JAK3 2746/4885JAK2 642/4885 |
| US-20160115168-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | BTK, JAK2, SYK | TGFBR1 2185/4885JAK3 12/4885JAK2 2/4885 |
| US-12544448-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | RICTOR, MTOR, MLST8 | TGFBR1 1938/4885JAK3 1613/4885JAK2 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.